Vor Biopharma (NYSE:VOR) Given New $3.00 Price Target at Barclays

Vor Biopharma (NYSE:VOR) had its price objective reduced by Barclays from $10.00 to $3.00 in a report issued on Wednesday morning, Benzinga reports. They currently have an overweight rating on the stock.

VOR has been the subject of several other research reports. Oppenheimer reissued an outperform rating and set a $10.00 target price (down previously from $15.00) on shares of Vor Biopharma in a research note on Monday, May 13th. Wedbush restated an outperform rating and issued a $11.00 price objective on shares of Vor Biopharma in a report on Friday, May 10th. Finally, JMP Securities reaffirmed a market outperform rating and issued a $12.00 target price on shares of Vor Biopharma in a research report on Monday, May 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma presently has an average rating of Buy and an average price target of $10.92.

Vor Biopharma Trading Up 6.2 %

Shares of VOR opened at $0.95 on Wednesday. Vor Biopharma has a 12-month low of $0.70 and a 12-month high of $3.14. The firm has a market capitalization of $65.05 million, a P/E ratio of -0.53 and a beta of -0.34. The firm has a 50-day moving average price of $1.00 and a 200 day moving average price of $1.59.

Vor Biopharma (NYSE:VOR) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). Equities research analysts predict that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after purchasing an additional 69,436 shares during the period. Renaissance Technologies LLC increased its stake in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after buying an additional 160,642 shares during the period. Acadian Asset Management LLC lifted its holdings in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after buying an additional 27,597 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vor Biopharma during the 2nd quarter worth approximately $63,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma in the 2nd quarter valued at approximately $53,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.